Apply to Attend – Only 500 Passes Available
Attendance at Advanced Therapies Europe 2025 is strictly limited to 500 curated participants to ensure every conversation delivers value. Whether you're driving biotech investment, scaling cell and gene therapy manufacturing, or preparing your next therapeutic breakthrough, your experience at ATE will be tailored, targeted, and designed to deliver real outcomes.
Super Early Bird - SOLD OUT!
Early Bird pricing ends 30 May — apply today to secure your place at one of Europe’s most exclusive events for senior biotech, pharma, and investment leaders.
This ticket is strictly for therapeutic developers, pharma, gov/regulators, academics, start-ups, and non-profits.
This ticket is best for CDMOs, CROs, service providers, consultants, and solution providers supporting the advanced therapies sector.
This ticket is for senior executives, investors, and industry leaders looking for an exclusive event experience.
Download the 2024 attendee list
)
)
)
)
)
)
)
)
)
)